Sangeetha Venugopal, M.D., is a board-certified hematologist who trained at renowned institutions, including Montefiore Medical Center and the Icahn School of Medicine at Mount Sinai in New York, and completed an additional leukemia-focused fellowship at the UT MD Anderson Cancer Center in Houston, Texas.
A well-published clinician-investigator, Dr. Venugopal focuses research on improving treatment outcomes for patients with myeloid malignancies, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN), through clinical trials, translational investigations, and precision medicine approaches. Dr. [Name] has a particular interest in identifying novel targeted therapies, elucidating mechanisms of treatment resistance, and developing strategies to eradicate measurable residual disease in AML.